Compare

Idorsia Ltd/€IDIA

1D1W1MYTD1Y5YMAX

About Idorsia Ltd

Idorsia Ltd is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company focuses on the discovery, development, and commercialization of innovative medicines. Idorsia’s pipeline includes treatments for a variety of conditions, with a particular emphasis on central nervous system disorders, cardiovascular diseases, and rare diseases. Notably, it was founded in June 2017 as a spinoff from Actelion, following its acquisition by Johnson & Johnson. Idorsia leverages its deep scientific expertise to progress its drug candidates from early-stage research through clinical development, aiming to address significant unmet medical needs. Sources: - Company Website - Publicly available financial and corporate reports
Ticker
€IDIA
Sector
Health
Primary listing
XGAT
Employees
456
Headquarters
Allschwil, Switzerland
Website
www.idorsia.com

Idorsia Ltd Metrics

BasicAdvanced
€1.3B
-
-€1.39
1.66
-

Bulls say / Bears say

QUVIVIQ sales rose 62% year on year to CHF 91 million in H1 2026, and Idorsia reaffirmed its CHF 200 million full-year target. That gives the company a growing commercial product rather than only a research pipeline. (Idorsia)
Idorsia is expanding QUVIVIQ through regional partners, including a new Saudi Arabia and Levant agreement that brings upfront, milestone and royalty income while leaving local promotion to Jamjoom Pharma. This could widen sales without requiring Idorsia to build every market itself. (Idorsia)
The pipeline offers several future value catalysts: positive Phase 2 paediatric daridorexant data, a planned pivotal lucerastat programme for Fabry disease, and late-stage selatogrel and cenerimod studies run with Viatris. Success in any of these could reduce Idorsia’s reliance on QUVIVIQ. (Idorsia, Idorsia)
Growth has not yet produced profitability. Idorsia reported a CHF 54 million non-GAAP operating loss in H1 2026 and still guides to an approximately CHF 120 million non-GAAP operating loss for the full year. (Idorsia)
The balance sheet remains highly leveraged despite the refinancing. At 30 June, Idorsia reported CHF 1.397 billion of total indebtedness against CHF 89 million of liquidity, while the new Pharmakon facility carries a fixed 7% interest rate. (Idorsia, Idorsia)
Much of the next growth story is still unproven or distant: TRYVIO/JERAYGO revenue is excluded from 2026 guidance, its launch is being developed around third-party financing and partners, and lucerastat may not reach a regulatory filing until as early as 2029. (Idorsia, Idorsia)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.

Idorsia Ltd Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Idorsia Ltd Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.